Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

The Microbiome and Clinical Outcome Among Patients with Multiple Myeloma (MM) Following CD38-Directed Antibody Treatment

Myo Htut, Keehoon Lee, Nitya Nathwani, Michael Rosenzweig, Murali Janakiram, Scott R. Goldsmith, James F. Sanchez, Martha Scott, Jonathan Keats, Amrita Y Krishnan, Steven T. Rosen, Sophia S. Wang

Blood (2024) 144 (Supplement 1): 1941.

https://doi.org/10.1182/blood-2024-206314

Published: 2024

Journal Articles

Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium

Murali Janakiram, Carlyn Rose Tan, Rakesh Popat, Joaquín Martínez Lopez, Efstathios Kastritis, Chris Lau, Wee-Joo Chng, Prashant Kapoor, Hira Mian, Susan Bal, Ajay K. Nooka, Andre De Menezes Silva Corraes, Magdalena Corona, Arnab Chowdhury, Yi Lin, Thomas G Martin, Amrita Y Krishnan

Blood (2024) 144 (Supplement 1): 3368.

https://doi.org/10.1182/blood-2024-211167

Published: 2024

Journal Articles

North American Adult T-Cell Leukemia Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist

Eric Liu, Amit Verma, Kith Pradhan, Urvi A. Shah, Aditi Shastri, Erik Guillen, Alejandro Sica, Gregoire Lauvau, Murali Janakiram, Paul D. Kassner

Blood (2024) 144 (Supplement 1): 1591.

https://doi.org/10.1182/blood-2024-210385

Published: 2024

Journal Articles

Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma

Blood (2024) 144 (Supplement 1): 2791.

https://doi.org/10.1182/blood-2024-206160

Published: 2024

Journal Articles

Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification

Blood (2024) 144 (Supplement 1): 3307.

https://doi.org/10.1182/blood-2024-201590

Published: 2024

Journal Articles

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2024-199609

Published: 2024

Journal Articles

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Lauren C. Peres, Alicia Richards, Surbhi Sidana, Laura B. Oswald, Danai Dima, Aimaz Afrough, Leyla O. Shune, Shonali Midha, Omar Castaneda, Christopher Ferreri, James A Davis, Oren Pasvolsky, Christen M. Dillard, Megan M Herr, Mehmet H. Kocoglu, Shebli Atrash, Brandon Blue, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Mahmoud R. Gaballa, Peter A. Forsberg, Ciara Louise Freeman, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Djordje Atanackovic, Binod Dhakal, Jack Khouri, Shahzad Raza, Ran Reshef, Melissa Alsina, Frederick L. Locke, Omar Nadeem, Faiz Anwer, Larry D Anderson, Jr., Shambavi Richard, Yi Lin, Thomas Martin, Peter M. Voorhees, Krina K. Patel, Doris K. Hansen, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2024-210078

Published: 2024

Journal Articles

Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients

Blood (2024) 144 (Supplement 1): 3067.

https://doi.org/10.1182/blood-2024-208199

Published: 2024

Journal Articles

The Association between Cumulative Excess Body Mass Index Exposure and Change in Monoclonal Protein Level in Veterans Diagnosed with Monoclonal Gammopathy of Undetermined Significance

Lawrence W Liu, Ekaterina Proskuriakova, Mei Wang, Murali Janakiram, Martin William Schoen, Kristen M. Sanfilippo, Theodore Thomas, Su-Hsin Chang

Blood (2024) 144 (Supplement 1): 6885.

https://doi.org/10.1182/blood-2024-206269

Published: 2024

Journal Articles

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla O. Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Chris Ferreri, Omar Castaneda, James A Davis, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud R. Gaballa, Megan M Herr, Peter A. Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara Louise Freeman, Frederick L. Locke, Peter M. Voorhees, Larry D Anderson, Jr., Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, Surbhi Sidana

Blood (2024) 144 (Supplement 1): 936.

https://doi.org/10.1182/blood-2024-194390

Published: 2024

Journal Articles

Impact of Age and Race on Survival in Adult T-Cell Leukemia/Lymphoma in the United States

Madeline G D'Agostino, B. Hilda Ye, Murali Janakiram, Dennis L Cooper, Ioannis Mantzaris, Aditi Shastri, Mendel Goldfinger, Noah Kornblum, Nishi Shah, Amit Verma, Lauren Shapiro, Ridhi Gupta, Yang Shi, Yanhua Wang, Alyssa De Castro, John X Wei, R. Alejandro Sica

Blood (2024) 144 (Supplement 1): 7732.

https://doi.org/10.1182/blood-2024-208561

Published: 2024

Journal Articles

Post-Transplantation Cyclophosphamide and Abatacept Graft-Versus-Host-Disease Prophylaxis Shows Improved Outcomes in North American Adult T-Cell Leukemia/Lymphoma

Blood (2024) 144 (Supplement 1): 7367.

https://doi.org/10.1182/blood-2024-207521

Published: 2024

Journal Articles

Mogamulizumab Shows Significant Activity with Tolerable Toxicity in a Real-World North American Adult T-Cell Leukemia/Lymphoma (ATLL) Cohort

Blood (2024) 144 (Supplement 1): 6418.

https://doi.org/10.1182/blood-2024-210619

Published: 2024

Journal Articles

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Blood blood.2024025945.

https://doi.org/10.1182/blood.2024025945

Published: 2024

Includes: Supplemental data

Journal Articles

North American Adult T-Cell Leukemia/Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist, CCR4-351

B. Hilda Ye, Eric Liu, Kith Pradhan, Erik Guillen, Urvi A Shah, Aditi Shastri, Gregoire Lauvau, Murali Janakiram, Alejandro Sica, Paul D. Kassner, Amit Verma

Blood (2023) 142 (Supplement 1): 6108.

https://doi.org/10.1182/blood-2023-191045

Published: 2023

Journal Articles

Clonal Hematopoiesis Is Associated with Severe Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Scott R. Goldsmith, Geoffrey P. Shouse, F. Lennie Wong, Alysia Bosworth, Aleksi Iujuridze, Sitong Chen, June-Wha Rhee, Matthew G. Mei, Murali Janakiram, Myo Htut, Stephen J. Forman, Raju Pillai, L. Elizabeth Budde, Saro Armenian

Blood (2023) 142 (Supplement 1): 4814.

https://doi.org/10.1182/blood-2023-185157

Published: 2023

Journal Articles

Efficacy of Bispecific Antibodies Vs CAR-T in the Treatment of Extramedullary Disease and High-Risk Cytogenetics in Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis

Charan Thej Reddy Vegivinti, Jaison Lawrence Alexander Santhi, Lawrence Liu, Praneeth Reddy Keesari, Rahul Thakur, M Bakri Hammami, Venkatesh Kapu, Sindhu Pericherla, Murali Mohan reddy Gopireddy, Nagarathna Poojary, Ananta Ghimire, Nishi Shah, Murali Janakiram

Blood (2023) 142 (Supplement 1): 1994.

https://doi.org/10.1182/blood-2023-190019

Published: 2023

Journal Articles

Prior Immune Effector Cell Therapy, Is Not Associated with an Increased Infectious Risk of Subsequent Bispecific Antibody Therapy for Multiple Myeloma

Lawrence Liu, Scott R. Goldsmith, Sheryl Leahey, Carlos Gomez Luna, Shawn Streeter, Adam Braun, Nitya Nathwani, Michael Rosenzweig, Firoozeh Sahebi, Azra Borogovac, Jonathan Keats, Myo Htut, Arnab Chowdhury, Sanjeet Singh Dadwal, Amrita Krishnan, Murali Janakiram

Blood (2023) 142 (Supplement 1): 1987.

https://doi.org/10.1182/blood-2023-188077

Published: 2023

Journal Articles

Monoclonal Gammopathy of Undetermined Significance and Risk of Cardiovascular Disease in US Veterans

Lawrence Liu, Niharika Pant, Mei Wang, Nikhil Grandhi, Ekaterina Proskuriakova, Murali Janakiram, Theodore Thomas, Kristen M. Sanfilippo, Graham Colditz, Daphne R Friedman, Martin William Schoen, Su-Hsin Chang

Blood (2023) 142 (Supplement 1): 4773.

https://doi.org/10.1182/blood-2023-185155

Published: 2023

Journal Articles

A Novel Approach to Achieve Long-Lasting Antitumor Immunity in Multiple Myeloma

Metin Gunes, Jessica Dang, Yate-Ching Yuan, Idit Shachar, Murali Janakiram, Mingye Feng, Steven T. Rosen, Emine Gulsen Gunes

Blood (2022) 140 (Supplement 1): 7092–7093.

https://doi.org/10.1182/blood-2022-167036

Published: 2022

NARROW

The Microbiome and Clinical Outcome Among Patients with Multiple Myeloma (MM) Following CD38-Directed Antibody Treatment

Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium

North American Adult T-Cell Leukemia Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist

Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma

Assessing the Performance of the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Model in a Multicultural Bronx Cohort: Implications for Monoclonal Gammopathy of Undetermined Significance (MGUS) Risk Stratification

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Promising Safety and Efficacy Data for Peginterferon Alfa-2a (PEG-IFN) and Bictegravir/Emtricitabine/Tenofovir Alafenamide (Biktarvy) in a North American Adult T-Cell Leukemia Lymphoma (NA-ATLL) Cohort of Patients

The Association between Cumulative Excess Body Mass Index Exposure and Change in Monoclonal Protein Level in Veterans Diagnosed with Monoclonal Gammopathy of Undetermined Significance

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Impact of Age and Race on Survival in Adult T-Cell Leukemia/Lymphoma in the United States

Post-Transplantation Cyclophosphamide and Abatacept Graft-Versus-Host-Disease Prophylaxis Shows Improved Outcomes in North American Adult T-Cell Leukemia/Lymphoma

Mogamulizumab Shows Significant Activity with Tolerable Toxicity in a Real-World North American Adult T-Cell Leukemia/Lymphoma (ATLL) Cohort

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

North American Adult T-Cell Leukemia/Lymphoma Has Frequent Mutations in CCR4 and Responds in Vitro to a Small Molecule CCR4 Antagonist, CCR4-351

Clonal Hematopoiesis Is Associated with Severe Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Efficacy of Bispecific Antibodies Vs CAR-T in the Treatment of Extramedullary Disease and High-Risk Cytogenetics in Relapsed Multiple Myeloma: A Systematic Review and Meta-Analysis

Prior Immune Effector Cell Therapy, Is Not Associated with an Increased Infectious Risk of Subsequent Bispecific Antibody Therapy for Multiple Myeloma

Monoclonal Gammopathy of Undetermined Significance and Risk of Cardiovascular Disease in US Veterans

A Novel Approach to Achieve Long-Lasting Antitumor Immunity in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only